Bas Israël
0000-0003-4848-4537
Radboudumc
23 papers found
Refreshing results…
Global Variation in Magnetic Resonance Imaging Quality of the Prostate
Ferumoxtran-10-enhanced 3-T Magnetic Resonance Angiography of Pelvic Arteries: Initial Experience
Implications of the European Association of Urology Recommended Risk Assessment Algorithm for Early Prostate Cancer Detection
Reply to Kamal Kant Sahu’s Letter to the Editor re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.012
Validation of In Vivo Nodal Assessment of Solid Malignancies with USPIO-Enhanced MRI: A Workflow Protocol
Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 4: Transperineal Magnetic Resonance–Ultrasound Fusion Guided Biopsy Using Local Anesthesia
Clinical implementation of pre‐biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer
External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging
Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men
Head-to-head comparison of 68Ga-prostate-specific membrane antigen PET/CT and ferumoxtran-10 enhanced MRI for the diagnosis of lymph node metastases in prostate cancer patients
Prediction of prostate cancer in biopsy-naive men: Diagnostic accuracy and external validation of current prostate cancer risk calculators
Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology
The SelectMDx urinary-biomarker test: Role in the detection of high-grade prostate cancer and in combination with multi-parametric magnetic resonance imaging in a contemporary prospective cohort of biopsy-naïve men
Focus on the Quality of Prostate Multiparametric Magnetic Resonance Imaging: Synopsis of the ESUR/ESUI Recommendations on Quality Assessment and Interpretation of Images and Radiologists’ Training
ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists’ training
Can Biparametric Prostate Magnetic Resonance Imaging Fulfill its PROMIS?
Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition
Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation
Reply to Arnaldo Stanzione, Massimo Imbriaco, and Renato Cuocolo’s Letter to the Editor re: Marloes van der Leest, Bas Israël, Eric Bastiaan Cornel, et al. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. Eur Urol 2019;76:574–81. Are We Meeting Our Standards? Stringent Prostate Imaging Reporting and Data System Acquisition Requirements Might be Limiting Prostate Accessibility
Reply to Jochen Walz. Let's Keep It at One Step at a Time: Why Biparametric Magnetic Resonance Imaging Is Not the Priority Today. Eur Urol 2019;76:582–3
Missing publications? Search for publications with a matching author name.